James Brian Houston

James Brian Houston

Auto-generated profile, based on publicly available information

James Brian Houston

University of Manchester

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2011 in Drug Metabolism and Disposition
Verified
Journal Article
Closed access
YYYoshiyuki Yabe
Yoshiyuki Yabe
AGAleksandra Galetin
Aleksandra Galetin
JHJ. Brian Houston
J. Brian Houston
To explore the determinants of hepatic uptake, 16 compounds were investigated with different physicochemical and disposition characteristics, including five statins, three sartans, saquinavir, ritonavir, erythromycin, clarithromycin, nateglinide, repaglinide, fexofenadine, and bosentan. Freshly isolated rat hepatocytes in suspension were used with the oil-spin method to generate kinetic parameters. Clearances, via passive diffusion (P(diff)) and active uptake (CL(active), characterized by maximal uptake rate and K(m)), were estimated from the initial uptake rate data over a 0.01 to 100 μM concentration range. The K(m) values had a range of 15-fold, with 10 of the 16 drugs with K(m) < 10 μM (median 6 μM). Both CL(active) and P(diff) ranged over 100-fold (median 188 and 14 μl/min/10⁶ cells). Assessment of the relative contribution of P(diff) and CL(active) indicated that, at low concentrations (approximately 0.1 μM), the active process contributes >80% to the overall uptake for 13 drugs. Although high P(diff) values were obtained for ritonavir and repaglinide, active process contributed predominantly to uptake; in contrast, high passive permeability dominates over transporter-mediated uptake for saquinavir over the full concentration range. For bosentan and erythromycin, active and passive processes were equally important. Hepatocyte-to-medium unbound concentration ratio was >10 for 9 of the 16 drugs, ranging from 2 to 494 for bosentan and atorvastatin, respectively. Some drugs showed extensive intracellular binding (fraction unbound range 0.01-0.6), which was not correlated with active uptake. LogD₇.₄ correlated significantly with P(diff) and the extent of intracellular binding but not with active uptake. This study provides systematic assessment of the role of active uptake relative to the passive process; implications of the findings are discussed.

2 August 2020 in ChemMedChem
Verified
Journal Article
Closed access
PDF file
LDLi Di
Li Di
PAPer Artursson
Per Artursson
AAAlex Avdeef
Alex Avdeef
LBLeslie Zachary Benet
Leslie Zachary Benet
JHJ. Brian Houston
J. Brian Houston
KSKiyohiko Sugano
Kiyohiko Sugano

1 March 2019 in Drug Metabolism and Disposition
Verified
Journal Article
Open access
PDF file
NMNorikazu Matsunaga
Norikazu Matsunaga
AUAyşe Ufuk
Ayşe Ufuk
BMBridget L. Morse
Bridget L. Morse
DBDavid W. Bedwell
David W. Bedwell
JBJingqi Bao
Jingqi Bao
AGAleksandra Galetin
Aleksandra Galetin
In the present study the beagle dog was evaluated as a preclinical model to investigate organic anion transporting polypeptide (OATP)-mediated hepatic clearance. In vitro studies were performed with nine OATP substrates in three lots of plated male dog hepatocytes +/- OATP inhibitor cocktail to determine total uptake (CLuptake), total and unbound cell-to-medium concentration ratio (Kpuu). In vivo intrinsic hepatic clearances (CLint,H) were determined following intravenous drug administration (0.1 mg/kg) in male beagle dogs. The in vitro parameters were compared to those previously reported in plated human, monkey and rat hepatocytes; the ability of cross species scaling factors to improve prediction of human in vivo clearance was assessed. CLuptake in dog hepatocytes ranged from 9.4-135 μL/min/106cells for fexofenadine and telmisartan, respectively. Active process contributed >75% to CLuptake for 5/9 drugs. Rosuvastatin and valsartan showed Kpuu>10, whereas cerivastatin, pitavastatin, repaglinide and telmisartan had Kpuu<5. The extent of hepatocellular binding in dog was consistent with other preclinical species and humans. The bias (2.73-fold) obtained from comparison of predicted vs. in vivo dog CLint,H was applied as an average empirical scaling factor (ESF av) for in vitro-in vivo extrapolation of human CLint,H. The ESF av based on dog reduced under-prediction of human CLint,H for the same dataset (gmfe=2.1), highlighting its utility as a preclinical model to investigate OATP-mediated uptake. The ESF av, from all preclinical species resulted in comparable improvement of human clearance prediction, in contrast to drug specific empirical scalars, rationalized by species differences in expression and/or relative contribution of particular transporters to drug hepatic uptake.

1 October 1994 in Pharmaceutical Research
Verified
Journal Article
Closed access
PDF file
JDJohn D. Davis
John D. Davis
LALeon Aarons
Leon Aarons
JHJ. Brian Houston
J. Brian Houston